SCHEMBL7983949

SCHEMBL7983949

Nc1c([N+](=O)[O-])cc(Br)c2c1CN(Cc1ccc(C(F)(F)F)cc1)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 2/20 0.43
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
COMT P21964 1/20 0.41
CYP19A1 P11511 1/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
CLPP Q16740 7/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CYP3A4 P08684 1/20 0.37
GPR132 Q9UNW8 1/20 0.37
ABCB1 P08183 1/20 0.36
ABCC1 P33527 1/20 0.36
ACACB O00763 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7983931 0.96 DRD4 (0.43) DRD4DRD2DRD3MAPK1NPSR1
SCHEMBL7970219 0.86 MEN1 (0.46) DRD4DRD2DRD3MAPK1ALDH1A1
SCHEMBL9091690 0.86 CYP19A1 (0.39) DRD2MAPK1CYP19A1ALDH1A1CA12
SCHEMBL7983703 0.85 BRS3 (0.45) DRD2DRD3MAPK1NPSR1CYP19A1
SCHEMBL7981495 0.81 MEN1 (0.46) DRD4DRD2DRD3MAPK1ALDH1A1
SCHEMBL8188636 0.80 KDM4E (0.45) DRD4DRD2DRD3COMTALDH1A1
SCHEMBL6780229 0.77 GRIA1 (0.51) ALDH1A1CYP3A4
SCHEMBL7980894 0.77 GAA (0.45) DRD4DRD2DRD3MAPK1NPSR1
SCHEMBL7981914 0.75 SIGMAR1 (0.45) DRD4DRD2DRD3ALDH1A1KDM4E
SCHEMBL7984183 0.74 SIGMAR1 (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6197771-B1 NERVOUS SYSTEM DISORDERS; ANTIISCHEMIC AGENTS; ALZHEIMER'SDISEASE; PARKINSON'S DISEASE; HUNTINGTON'S DISEASE WARNER-LAMBERT COMPANY 2001-03-06 US claimed
WO-1996028445-A1 NOVEL GLUTAMATE (AMPA/KAINATE) RECEPTOR ANTAGONISTS: N-SUBSTITUTED FUSED AZACYCLOALKYLQUINOXALINEDIONES WARNER-LAMBERT COMPANY (US) 1996-09-19 WO claimed
US-6197771-B1 NERVOUS SYSTEM DISORDERS; ANTIISCHEMIC AGENTS; ALZHEIMER'SDISEASE; PARKINSON'S DISEASE; HUNTINGTON'S DISEASE WARNER-LAMBERT COMPANY 2001-03-06 US disclosed
US-6057313-A TREATING CENTRAL NERVOUS SYSTEM DISORDERS WARNER-LAMBERT COMPANY (US) 2000-05-02 US disclosed
WO-1996028445-A1 NOVEL GLUTAMATE (AMPA/KAINATE) RECEPTOR ANTAGONISTS: N-SUBSTITUTED FUSED AZACYCLOALKYLQUINOXALINEDIONES WARNER-LAMBERT COMPANY (US) 1996-09-19 WO disclosed